2000 Participants Needed

Clonal Hematopoiesis for Blood Disorders

SL
Overseen BySwisher Lab Research Coordinators
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: University of Washington
Must be taking: Platinum-based chemotherapy, PARP inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores why some individuals with ovarian or other solid cancers develop blood cancers after treatment. Researchers examine blood samples and medical histories to identify any genetic or environmental causes of these blood cancers. The trial includes individuals who have had ovarian, peritoneal, or fallopian tube cancer and completed a specific amount of chemotherapy, as well as those with a solid tumor who have used certain cancer drugs or have certain blood disorders. Participants provide blood samples and share their medical records to help identify these risk factors. As an unphased trial, this study allows participants to contribute to groundbreaking research that could enhance the understanding and prevention of blood cancers.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover how clonal hematopoiesis—essentially changes in blood cells—might lead to myeloid neoplasms, a type of blood cancer, in cancer patients. Unlike standard treatments that directly target cancer cells, this study focuses on understanding underlying risk factors by analyzing blood samples and medical records. The goal is to identify potential early indicators of cancer development, which could lead to more personalized and preventative approaches in the future.

Who Is on the Research Team?

ES

Elizabeth Swisher

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Are You a Good Fit for This Trial?

Inclusion Criteria

I have completed or will complete at least 5 rounds of platinum-based chemotherapy.
I have been treated with a PARP inhibitor for 4+ months or have a diagnosed blood disorder.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Patients undergo blood sample collection and complete surveys. Medical records are reviewed.

Up to 5 years

Follow-up

Participants are monitored for safety and effectiveness after observational activities

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Non-Interventional Study

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: ObservationalExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Washington

Lead Sponsor

Trials
1,858
Recruited
2,023,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+